Video

Dr. Marks on how PSMA imaging is “opening doors” in prostate cancer

Author(s):

Urology Times staff

“We call this a ‘disruptive innovation,’” says Leonard S. Marks, MD.

In this video, Leonard S. Marks, MD, explains how the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer will affect urologists and patients alike. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.

Related Videos
Diverse group of doctors | © Flamingo Images - stock.adobe.com
Man talking with a doctor | Image Credit: © RFBSIP - stock.adobe.com
Evan Panken, MD, answers a question during a video interview
Illustration of Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
Amy Pearlman, MD, answers a question during a video interview
Team of surgeons | Image Credit: © shefkate - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Related Content
Trial launches of 61Cu-based radiotracer in PSMA-positive prostate cancer
October 23rd 2024

Trial launches of 61Cu-based radiotracer in PSMA-positive prostate cancer

Hannah Clarke
The trial is comparing the diagnostic performance of 61Cu-NODAGA-PSMA I&T with that of 18F-piflufolastat.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
18F rhPSMA-7.3 PET/MRI demonstrates high detection in recurrent prostate cancer
October 15th 2024

18F rhPSMA-7.3 PET/MRI demonstrates high detection in recurrent prostate cancer

Hannah Clarke
Overall, 15/16 patients had a true positive scan based on confirmatory imaging and/or biopsy, equating to a PPV of 93.75%.
Phase 3 trial of 64Cu-SAR-bisPSMA in BCR of prostate cancer set to launch in 2025
October 14th 2024

Phase 3 trial of 64Cu-SAR-bisPSMA in BCR of prostate cancer set to launch in 2025

Hannah Clarke
Patient recruitment for the phase 3 AMPLIFY trial is set to begin early next year.
Collaboration to support clinical development of PSMA-targeting theranostics in Japan
October 14th 2024

Collaboration to support clinical development of PSMA-targeting theranostics in Japan

Hannah Clarke
Both 177Lu-PSMA-I&T and 64Cu-PSMA-I&T are currently in phase 3 development for use in prostate cancer diagnostics and treatment.
Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting
October 10th 2024

Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting

Urology Times staff
"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.
© 2024 MJH Life Sciences

All rights reserved.